Targeting thymidylate synthase enhances CD8 + T-cell infiltration and inhibits tumor growth in cervical cancer
Medical Oncology · 2026
DOI: 10.1007/s12032-026-03250-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, 2026. Verfasst von Yongyan Pei und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan Campus, No.13 Changmingshui Avenue, Wuguishan, Zhongshan…. Hauptthemen laut MEDLINE: Thymidylate Synthase, Uterine Cervical Neoplasms, CD8-Positive T-Lymphocytes, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Guangdong Medical Research Foundation.
Abstract (Originalsprache)
Cervical cancer (CESC) presents a significant clinical challenge, primarily due to an incomplete understanding of the immunometabolic crosstalk within the tumor microenvironment (TME) and the lack of reliable biomarkers for immunotherapy stratification. Thymidylate synthase (TYMS), a pivotal enzyme in nucleotide synthesis, has been implicated in tumor progression, but its role as an immunometabolic regulator in CESC remains unexplored. Through an integrative approach combining single-cell RNA sequencing (scRNA-seq) of 47,589 cells, bulk transcriptomics, functional assays, and in vivo modeling, we delineated the multifaceted functions of TYMS. scRNA-seq analysis revealed a dynamic shift from CD4 + to exhausted CD8 + T-cell dominance during progression, orchestrated by specific ligand-receptor interactions like PTPRC-MRC1. A robust T cell-associated prognostic signature comprising TYMS, MYO6, SPINT1 and ESD was developed, effectively stratifying patients into distinct risk groups with differential tumor stemness, immune infiltration, and response to immunotherapy. Mechanistically, TYMS silencing promoted tumor stemness, migration, and invasion in vitro via targeting miR-197-3p. Crucially, in immunocompetent micemodel, TYMS knockdown accelerated tumor growth and potently suppressed CD8 + T-cell infiltration, demonstrating its role in promoting immune evasion. Conversely, TYMS overexpression suppressed tumorigenesis. Molecular docking identified Deoxyuridine Monophosphate as a high-affinity inhibitor of TYMS. Our findings demonstrate that targeting thymidylate synthase enhances CD8 + T-cell infiltration and inhibits tumor growth in cervical cancer, establishing TYMS as a promising therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan Campus, No.13 Changmingshui Avenue, Wuguishan, Zhongshan City, Guangdong Province, China. peiyongyan@gdpu.edu.cn.
- School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan Campus, No.13 Changmingshui Avenue, Wuguishan, Zhongshan City, Guangdong Province, China.
Förderung
- Guangdong Medical Research Foundation
Zitieren
APA
Pei, Y., Zhong, Z., Li, H., Tan, Y., & Cao, H. (2026). Targeting thymidylate synthase enhances CD8 + T-cell infiltration and inhibits tumor growth in cervical cancer. Medical Oncology. https://doi.org/10.1007/s12032-026-03250-5
Vancouver
Pei Y, Zhong Z, Li H, Tan Y, Cao H. Targeting thymidylate synthase enhances CD8 + T-cell infiltration and inhibits tumor growth in cervical cancer. Medical Oncology. 2026. doi:10.1007/s12032-026-03250-5
BibTeX
@article{Pei2026,
author = {Pei, Yongyan and Zhong, Zheng and Li, Hongliang and Tan, Yuanchang and Cao, Hua},
title = {Targeting thymidylate synthase enhances CD8 + T-cell infiltration and inhibits tumor growth in cervical cancer},
journal = {Medical Oncology},
year = {2026},
doi = {10.1007/s12032-026-03250-5}
}
EUVIMED